Celldex Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Celldex Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q2 2010 to Q3 2024.
  • Celldex Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $55.3M, a 29.4% increase year-over-year.
  • Celldex Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $197M, a 41.3% increase year-over-year.
  • Celldex Therapeutics, Inc. annual Costs and Expenses for 2023 was $161M, a 37.3% increase from 2022.
  • Celldex Therapeutics, Inc. annual Costs and Expenses for 2022 was $118M, a 54.9% increase from 2021.
  • Celldex Therapeutics, Inc. annual Costs and Expenses for 2021 was $75.9M, a 7.24% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $197M $55.3M +$12.6M +29.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $184M $48.8M +$15.3M +45.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $169M $40.8M +$7.33M +21.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $161M $51.8M +$22.3M +75.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $139M $42.8M +$14.7M +52.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $125M $33.5M -$3.09M -8.44% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $128M $33.4M +$10M +42.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $118M $29.5M +$8.83M +42.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $109M $28.1M +$7.13M +34% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $102M $36.6M +$19.6M +116% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $82M $23.4M +$6.11M +35.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $75.9M $20.7M -$7.89M -27.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $83.8M $21M +$5.97M +39.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $77.8M $16.9M +$5.32M +45.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $72.5M $17.3M +$1.73M +11.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $70.8M $28.6M +$14.7M +106% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $56.1M $15M +$2.62M +21.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $53.5M $11.6M -$1.37M -10.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $54.8M $15.6M -$3.77M -19.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $58.6M $13.9M -$12K -0.09% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $58.6M $12.4M +$3.69M +42.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $54.9M $13M -$6.66M -33.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $61.6M $19.4M -$104M -84.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $166M $13.9M -$15.1M -52.1% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-29
Q3 2018 $181M $8.71M -$27.2M -75.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $208M $19.6M -$13.1M -40.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $221M $124M +$87.1M +238% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $134M $29M -$7.75M -21.1% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-26
Q3 2017 $142M $35.9M +$3.67M +11.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $138M $32.8M -$998K -2.96% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $139M $36.6M -$361K -0.98% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $140M $36.7M +$1.5M +4.25% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-07
Q3 2016 $138M $32.2M -$1.18M -3.55% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $139M $33.8M -$1.17M -3.36% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $141M $37M +$5.54M +17.6% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $135M $35.2M +$1.7M +5.08% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-07
Q3 2015 $133M $33.4M +$1.95M +6.21% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 $131M $34.9M +$5.79M +19.9% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $126M $31.5M -$438K -1.37% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 $126M $33.5M +$10.8M +47.5% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-14
Q3 2014 $115M $31.4M +$7.19M +29.7% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-05
Q2 2014 $108M $29.1M +$10.4M +55.4% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 $97.6M $31.9M +$12.1M +61% Jan 1, 2014 Mar 31, 2014 10-Q 2015-04-29
Q4 2013 $85.6M $22.7M +$2.54M +12.6% Oct 1, 2013 Dec 31, 2013 10-K/A 2016-02-25
Q3 2013 $83M $24.2M +$6.39M +35.7% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-05
Q2 2013 $76.6M $18.8M +$3.26M +21% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-07
Q1 2013 $73.4M $19.8M +$4.09M +26% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-01
Q4 2012 $69.3M $20.2M +$5.38M +36.3% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-24
Q3 2012 $63.9M $17.9M +$4.02M +29.1% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 $59.9M $15.5M +$3.66M +31% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-06
Q1 2012 $56.2M $15.7M +$3.55M +29.1% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-03
Q4 2011 $52.7M $14.8M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-03
Q3 2011 $13.8M +$2.55M +22.6% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-02
Q2 2011 $11.8M -$404K -3.3% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-09
Q1 2011 $12.2M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
Q3 2010 $11.3M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 $12.2M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.